{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:19:49Z","timestamp":1767989989103,"version":"3.49.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is an autoimmune disorder primarily affecting the neuromuscular junction. Muscle-specific receptor tyrosine kinase\u00a0antibody (MuSK-Ab)-mediated MG often presents with bulbar weakness and is prone to crisis. Currently, conventional treatments show limited efficacy in\u00a0MuSK-Ab-mediated MG, while rituximab therapy demonstrates favorable outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a case of a patient who initially achieved symptom control with efgartigimod during an acute exacerbation but experienced symptom recurrence after subsequent rituximab treatment. Owing to poor tolerance to pyridostigmine and corticosteroids, and considering the established efficacy of efgartigimod in MuSK-Ab-positive MG, we opted for continued efgartigimod infusions. This approach quickly improved symptoms, achieved minimal symptom expression (MSE), and allowed faster tapering of corticosteroids and pyridostigmine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While multiple studies have demonstrated the efficacy and safety of efgartigimod, large-scale studies remain necessary to further evaluate the feasibility of combination therapy with rituximab in MuSK-Ab-positive MG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1710017","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:53:34Z","timestamp":1767768814000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiujun","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongtong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houshi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1275533","article-title":"Rituximab treatment in myasthenia gravis","volume":"14","author":"Vesperinas-Castro","year":"2023","journal-title":"Front Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard Jr","year":"2021","journal-title":"Lancet Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.36185\/2532-1900-038","article-title":"Myasthenia gravis: MuSK MG, late-onset MG and ocular MG","volume":"39","author":"Deymeer","year":"2020","journal-title":"Acta Myol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2025-004655","article-title":"Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)","volume":"25","author":"Jacob","year":"2025","journal-title":"Pract Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J Neurol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M116.064675","article-title":"A two-pronged binding mechanism of igG to the neonatal fc receptor controls complex stability and igG serum half-life","volume":"16","author":"Jensen","year":"2017","journal-title":"Mol Cell Proteomics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.03.001","article-title":"Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis","volume":"317","author":"Jensen","year":"2019","journal-title":"Exp Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e16189","DOI":"10.1111\/ene.16189","article-title":"Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center","volume":"31","author":"Frangiamore","year":"2024","journal-title":"Eur J Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12588-7","article-title":"A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients","volume":"271","author":"Pane","year":"2024","journal-title":"J Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s40478-022-01454-0","article-title":"Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy","volume":"10","author":"Fichtner","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1486659","article-title":"Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation","volume":"15","author":"Shi","year":"2024","journal-title":"Front Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"17562864251326778","DOI":"10.1177\/17562864251326778","article-title":"Efgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis","volume":"18","author":"Zhou","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1401972","article-title":"Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e200276","DOI":"10.1212\/CPJ.0000000000200276","article-title":"Therapeutic responses to efgartigimod for generalized myasthenia gravis in Japan","volume":"14","author":"Suzuki","year":"2024","journal-title":"Neurol Clin Pract"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1710017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:11:17Z","timestamp":1767971477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1710017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2025.1710017"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1710017","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1710017"}}